Novos métodos diagnósticos para a Síndrome dos Ovários Policísticos: avanços e biomarcadores promissores
##plugins.themes.bootstrap3.article.sidebar##
##plugins.themes.bootstrap3.article.main##
Resumo
Objetivo: Identificar e avaliar as novas formas de diagnóstico da Síndrome do Ovário Policístico (SOP), com foco em avanços tecnológicos, biomarcadores e critérios diagnósticos recentes que possam melhorar a acurácia e a precocidade do diagnóstico dessa condição. Métodos: Trata-se de uma revisão integrativa realizada com base em uma busca na base de dados PubMed Central (PMC), utilizando os termos de pesquisa "diagnosable" OR "diagnosis" AND "polycystic ovary syndrome". A busca inicial resultou em 1.241 artigos, dos quais 63 foram selecionados após a aplicação de critérios de inclusão e exclusão, resultando em 18 artigos relevantes para análise completa. Resultados: Os principais achados destacam avanços tecnológicos e biomarcadores promissores que podem contribuir para um diagnóstico mais preciso da SOP. As inovações discutidas no estudo sugerem que a combinação de novas metodologias pode levar a uma identificação mais rápida e eficaz da síndrome, beneficiando o manejo clínico das pacientes. Considerações finais: O estudo ressalta a importância de continuar a pesquisa em diagnósticos para a SOP, considerando as limitações atuais e a necessidade de mais evidências.
##plugins.themes.bootstrap3.article.details##
Copyright © | Todos os direitos reservados.
A revista detém os direitos autorais exclusivos de publicação deste artigo nos termos da lei 9610/98.
Reprodução parcial
É livre o uso de partes do texto, figuras e questionário do artigo, sendo obrigatória a citação dos autores e revista.
Reprodução total
É expressamente proibida, devendo ser autorizada pela revista.
Referências
2. ALADAG H, et al. Galectin-1 an a potential diagostic biomarker in polycystic ovary syndrome. European Review for Medical and Pharmacological Sciences, 2023; 27(6): 2543-2551.
3. BADEEB A, et al. Dark cortical rim: an MRI feature of polycystic ovarian syndrome. Abdominal Radiology, 2021; 46: 1148-1156.
4. BOZDAG G, et al. Anti-Müllerian Hormone as a Diagnostic Tool for Polycystic Ovary Syndrome Under Different Diagnostic Criteria Among Unselected Population. Reproductive BioMedicine Online, 2019; 39(3): 522-529.
5. CRAIG M, et al. Polycystic Ovarian Syndrome in Adolescents: Early Diagnosis and Intervention. Journal of Pediatric Health Care, 2020; 34(2): 166-170.
6. CUNDUBEY CR. Serum phoenixin-14 Levels of women with polycystic ovary syndrome increase proportionally with BMI. European Review For Medical And Pharmacological Sciences, 2023; 27(8): 3519-3525.
7. DESWAL R e DANG AS. Dissecting the role of micro-RNAs as a diagnostic marker for polycystic ovary syndrome: a systematic review and meta-analysis. Fertility and sterility, 2020; 113(3): 661-669.
8. EROGLU S e CAKMAKLIOGULLARI EK. Decreased serum profile of the interleukin-36α in polycystic ovary syndrome. Taiwanese Journal of Obstetrics and Gynecology, 2021; 60(6): 1018-1022.
9. GAO Q, et al. Exploration of molecular features of PCOS with different androgen levels and immune-related prognostic biomarkers associated with implantation failure. Frontiers in Endocrinology, 2022; 13: 946504.
10. HASEGAWA Y, et al. Impact of the difference in diagnostic criteria for adolescent polycystic ovary syndrome excluding polycystic ovarian morphology. Journal of Obstetrics and Gynaecology Research, 2024; 50: 1289–1294.
11. JARRETT BY, et at. Impact of right–left differences in ovarian morphology on the ultrasound diagnosis of polycystic ovary syndrome. Fertility and Sterility, 2019; 112(5): 939-946.
12. JIANG Y, et al. Serum asprosin level in diferente subtypes of polycytisc ovary syndrome: a cross-sectional study. Revista da Associação Médica Brasileira, 2021; 67 (4): 590-596.
13. LIU C, et al. The Associations Between Alanine Aminotransferase and Other Biochemical Parameters in Lean PCOS. Reproductive Sciences, 2023; 30(2): 633-641.
14. LONE NM, et al. Genotype-independent association between vitamin D deficiency and polycystic ovarian syndrome in Lahore, Pakistan. Scientific Reports, 2020; 10(1): 2290.
15. LONG J, et al. Screening for a Simple and Effective Indicator of Insulin Resistance in Chinese Reproductive-Aged Women, with the Insulin Clamp Technique as a Reference. Metabolic syndrome and related disorders, 2019; 17(8): 423-429.
16. MARTIN RF, et al. Glycoprotein A and B Height-to-Width Ratios as Obesity-Independent Novel Biomarkers of Low-Grade Chronic Inflammation in Women with Polycystic Ovary Syndrome (PCOS). Journal of proteome research, 2019; 18(11): 4038-4045.
17. PAALANNE M, et al. Clinical and biochemical signs of polycystic ovary syndrome in young women born preterm. European Journal of Endocrinology, 2021; 185(2): 279-288.
18. PARVEEN S, et al. Association of lipid profile and obesity in patients with polycystic ovary syndrome. Endocrine regulations, 2024; 58 (1): 83-90.
19. REDDY VS, et al. Circulatory Metastin/Kisspeptin-1 (META KISS-1 Study) in Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis with Diagnostic Test Accuracy. Reproductive BioMedicine Online, 2019; 39(4): 685-697.
20. RUDNICKA E, et al. Hormone in Pathogenesis, Diagnostic and Treatment of PCOS. International Journal of Molecular Sciences, 2021; 22(22): 12507.
21. TEMUR M, et al. Elevated circulating Selenoprotein P levels in patients with polycystic ovary syndrome. Journal of Obstetrics and Gynaecology, 2022; 42(2): 289-293.
22. WITCHEL SF, et al. Curtailing PCOS. Pediatric research, 2020; 87(2): 353-361.
23. ZHANG M, et al. The reference value of anti-Müllerian hormone to diagnose polycystic ovary syndrome is inversely associated with BMI: a retrospective study. Reproductive Biology and Endocrinology, 2023; 21(1): 15.